Rockin Robin SongFlying The Web For News.
RobinPost Logo Amazon Prime Deals





Globe NewsWire News Distribution Service


Geneva, Switzerland and Westport, CT, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Launched today, the Alliance for Advancing Bioelectronic Medicine (AABM) is an independent network of professionals united to advance bioelectronic medicine – one of the most innovative and exciting fields in healthcare. The alliance aims to align bioelectronic medicine leaders on shared goals, facilitate cross-sector collaboration, mobilize key external audiences, and build awareness of the field overall.

“Bioelectronic medicine represents a tremendous opportunity to improve patients’ lives and change our world. However, achieving this will require much greater collaboration and awareness from a much larger and more diverse group of stakeholders,” said Kenneth L. Londoner, Founder, CEO, and Chairman of BioSig Technologies, a medical technology company that has supported creation of AABM. “We believe that the Alliance for Advancing Bioelectronic Medicine will play a much-needed role by aligning and amplifying voices in the field, winning over new allies, and driving progress that, ultimately, benefits everyone.”

The alliance brings together leaders in bioelectronic medicine: a rapidly growing field of healthcare that explores how targeted electrical signals can harness the body’s natural mechanisms to diagnose and treat a range of diseases. Its members are committed to realizing the potential of bioelectronic medicine to transform diagnosis and care for millions of people, particularly in areas of unmet need such as Parkinson’s disease, major depressive disorder, treatment-resistant epilepsy, heart arrhythmia, and chronic pain.

“The Alliance for Advancing Bioelectronic Medicine will support greater collaboration among experts across different sectors, disease areas, disciplines, and specialties,” said Samuel Asirvatham, M.D. a founding member of AABM and Vice Chair, Innovation and Medical Director, Electrophysiology Laboratory, Cardiovascular Diseases at the Mayo Clinic. “The collaboration hopes to pave the way to novel diagnostics and treatment options for patients.”

 The alliance grew out of an invitation-only roundtable in the spring of 2019, at which a distinguished group of researchers, entrepreneurs, and healthcare experts agreed on the need for an ongoing dialogue to advance a shared vision for bioelectronic medicine and a catalyst to unite the field. Since that gathering, members have developed a consensus on a shared definition, a unified narrative, and a set of tailored messages for the many groups that stand to benefit from bioelectronic medicine.

“We’ve seen impressive scientific and medical progress in bioelectronic medicine in recent years,” said Dr. Hein Heidbuchel, Professor and Chair of Cardiology, Antwerp University and President of the European Heart Rhythm Association. “But what has been missing is a compelling story that builds understanding and support for this field across a wide range of relevant audiences.”

The Alliance for Advancing Bioelectronic Medicine aims to play a unique convening role, mobilizing patients, physicians, and other stakeholders to advocate for the field, and increasing awareness among audiences that are important for the field’s growth, including policymakers, investors, media, and the general public. Its steering committee includes experts with experience at Battelle, European Heart Rhythm Association, The Feinstein Institute, Heart Rhythm Society, Imperial College London, Mayo Clinic, RAND Corporation and Sheba Medical Center. 

The alliance will be coordinated by High Lantern Group, a strategic positioning firm active in global health policy. “We see great potential for bioelectronic medicine to help serve unmet medical needs and achieve healthier societies,” said Mario Ottiglio, Managing Director at High Lantern Group. “We look forward to collaborating with this community to shape a compelling policy agenda that attracts broad support and helps accelerate the growth of this nascent industry.”

For more information, please contact:

Ms. Julie Pierce

Managing Director

High Lantern Group 

Ms. Natasha Drapeau

Executive Vice President

BioSig Technologies, Inc.


This email address is being protected from spambots. You need JavaScript enabled to view it.

+1 203-409-5444, x119  

Meryl Ellingson
High Lantern Group
6263442722
This email address is being protected from spambots. You need JavaScript enabled to view it.


Posted: 2019-11-18 23:41:00

Get Full News Story On GlobeNewsWire Press Release Service


Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.



More News From This Category
Press Release: CORRECTION -- Emerita Resources Corp.
Wed, 07 Jan 2026 14:07:44 +0000

TORONTO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- In a release issued earlier today by Emerita Resources Corp. (TSX-V: EMO; OTCQB: EMOTF; FSE: LLJA), please note that a typo in the headline has been corrected — “12.1m Grading” instead of “2.1m Grading.” The corrected release follows:

Read More ...


Press Release: On 7 January 2026, Freudenberg Home and Cleaning Solutions GmbH announced a recommended public offer to the shareholders of Nilfisk Holding A/S to tender all outstanding shares in Nilfisk to Freudenberg
Wed, 07 Jan 2026 11:07:44 +0000

COPENHAGEN, Denmark, Jan. 07, 2026 (GLOBE NEWSWIRE) -- On 7 January 2026, Freudenberg Home and Cleaning Solutions GmbH (“Freudenberg”) announced a recommended public offer to the shareholders of Nilfisk Holding A/S (“Nilfisk” or the “Company”) to tender all outstanding shares in Nilfisk to Freudenberg at a price of DKK 140 for each share of nominally…

Read More ...


Press Release: World-renowned Immunologist and Distinguished Scientist Joins CancerVax as Senior Scientific Advisor
Wed, 07 Jan 2026 08:07:41 +0000

Lehi Utah, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Lehi, Utah, January 7, 2026 – CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform that uses the body’s immune system to treat cancer, today announced that Mark M. Davis, PhD will serve as the Company’s Senior Scientific Advisor.

Read More ...


Press Release: Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering
Wed, 07 Jan 2026 05:07:43 +0000

BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the pricing of its underwritten public offering of 2,212,000 shares of its common stock at a public…

Read More ...


Press Release: Nitric Boost Ultra Formulation Analysis: Male Wellness Industry Enters 2026 With Growing Interest in Nitric Oxide Support Supplements
Wed, 07 Jan 2026 02:07:44 +0000

LOS ANGELES, CA, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only. It is not medical advice. Always consult a qualified healthcare professional before starting supplements. If you purchase through links in this article, a commission may be earned at no additional cost to you.

Read More ...


Related Bing News Results
ME Group Completes Pre-A Extension Round and Acquires Video Production and Distribution Platform BTV
Tue, 06 Jan 2026 06:08:00 GMT
ME Group, a leading Web3 media and brand growth services institution, announced that it has secured strategic investments from FutureMoney Group and Bit Origin (Nasdaq: BTOG).

Mulvihill Enhanced Split Preferred Share ETF Declares Monthly Distribution
Wed, 03 Dec 2025 13:09:00 GMT
TORONTO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- (TSX: SPFD) Mulvihill Enhanced Split Preferred Share ETF has declared a monthly cash distribution in the amount of $0.08333 per unit, payable on February 6, ...














Blow Us A Whistle


Related Product Search/Búsqueda de productos relacionados

Amazon Logo